the 9th, NKCL Bio Group Inc.’s Chairman Dong-Hwa Shin has won the grand prize
in the ‘2022 Korea’s Influential CEO- Innovative Management Bio Sector’ hosted
by TV Chosun and Digital Chosun Ilbo.
'2022 Korea's Influential CEO' is awarded among the CEOs of companies and
institutions during the year to those who played a major role in the
development of each industry and economy through rigorous screening by
industry-academic experts and consumer research.
NKCL Bio Group’s
Chairman Dong-hwa Shin advanced the standard system in the innovative
management bio sector and reflected the changes in the NK cell and anti-cancer
drug market in advance to strengthen the quality competitiveness of NK cell
therapy products, and to lead the innovation management and bio sector for one
year, highly evaluated received.
NKCL Bio Group’s
Chairman Dong-Hwa Shin has been highly evaluated that he has been leading the
innovation management and bio fields for one year in the way that he has advanced
the standard system in the innovative management bio sector, strengthened the
quality competitiveness of NK cell therapy products by pre-reflecting up to date
changes in the NK cell and anticancer drug market.
Chairman Dong-hwa Shin said, “Although overall industrial activities have been
stagnant due to the COVID-19 pandemic, the domestic bio industry achieved high
export performance, due to the highlighted importance of vaccines that can
protect against the pandemic that threatens humanity, increased consignment
production of biopharmaceuticals, and domestic biosimilar business, expanding
its global market share,” he said.
“In the near
future, the portion of cell culture technology in the bio industry will further
expand.” he added.
On the other
hand, NKCL Bio Group Inc. is a bio company that researches and develops NK
immune cell therapy based on NK cells and applies GMP mass production
technology, and provides a ‘Personalized Immune Care Platform’ service.
NK cells are
cells in charge of the immune system in our body and maximize the ability to
kill cancer cells. NK cells are recognized for its importance as interest in
immunity has increased due to the COVID-19 pandemic.
the Korea Biotechnology Association, it is known that 60% of all cancer
treatment clinical trials are cell-based immunotherapy clinical trials. As the
development of immunotherapy drugs is in full swing, investment in
manufacturing plant facilities for commercialization of pharmaceuticals is also
NKCL is equipped with global-level manufacturing facilities, such as expanding
production facilities for NK cell therapy products that require advanced
technology and building a GMP facility capable of mass culture, and increasing
technological perfection through patent applications related to NK cells.
In addition, in Korea, other than NKCL Bio Group, ▲ NK Max ▲ Box Cell Bio ▲ SMT
Bio ▲ CHA Biotech ▲ Immunis Bio ▲ HK Innoen are also focusing on the
development of NK cell-based immune anticancer drugs, and investment has been
The reason why various companies have jumped
into the cell/therapeutic field is that, as promising domestic bio ventures
have the ability to develop cell/gene therapy, the possibility of developing
new domestic blockbuster drugs is gradually increasing.
According to the global market report TBRC
data, the global cell-based immunotherapy market is expected to grow by 17.0%
from $60.32 billion (76.4 trillion won) in 2021 to $70.59 billion (89 trillion
won) in 2022.
the '2022 Korea's Influential CEO' awards ceremony, which celebrated its 10th
anniversary this year, Starbucks Korea CEO Song Ho-seop (sustainability
management) and Genesis BBQ Group Chairman Yoon Hong-geun (global management)
won the awards for the second consecutive year, with a new award in 2022. In
the new award group for 2022, Lee Seok-woo, CEO of Dunamu (4th industry
management sector), and Shin Dong-hwa, chairman of NKCL Bio Group Inc. (innovative
management sector) were named together with the award.